RIPK1 and injury: Interestingly, however, the FDA-approved ATP-competitive BRAF inhibitor dabrafenib also inhibits human and mouse RIPK3 without cross-inhibition of RIPK1 and without adverse induction of RIPK1-dependent apoptosis and protects mice from acetaminophen-induced liver injury (137, 138).